ESMO2017 演題レポート Madrid, Spain 08 Sep - 12 Sep 2017

2017年9月8日~12日にスペイン・マドリードで開催された 2017年 欧州臨床腫瘍学会学術集会(ESMO 2017 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。


演題レポート

Special Session

#LBA21
大腸癌

Prospective pooled analysis of six phase III trials investigating duration of adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for patients with stage III colon cancer: Updated results of IDEA (International Duration Evaluation of Adjuvant Chemotherapy)

Axel Grothey, et al.

#LBA24
大腸癌

Efficacy of 3 versus 6 months of Oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: Results from phase III ACHIEVE trial as part of the international duration evaluation of adjuvant therapy (IDEA) collaboration

Takayuki Yoshino, et al.

Proffered Paper session

#LBA28
胃癌および食道胃接合部腺癌

KEYNOTE-059: Efficacy and safety of Pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal cancer

Zev A. Wainberg, et al.

#LBA29
胆道癌

Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Julien Edeline, et al.

#LBA30
肝細胞癌

Analysis of serum biomarkers in patients from a phase 3 study of Lenvatinib vs. Sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Richard S, Finn, et al.

#474O
大腸癌

Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and Irinotecan plus Bevacizumab versus m FOLFOX6 or CapeOX plus Bevacizumab as first-line treatment for metastatic colorectal cancer

Yoshito Komatsu, et al.

#475O
大腸癌

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): A randomized phase II trial of the AIO (AIO-KRK-0109)

Michael Geissler, et al.

#476O
大腸癌

Neoadjuvant FOLFOX4 versus FOLFOX4 plus Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicenter randomized controlled trial (PRODIGE 22)

Mehdi Karoui, et al.

#486O
大腸癌

Randomized phase III study of Fluoropyrimidine (FP) plus Bevacizumab (BEV) vs. FP plus Irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) - study

Dominik P. Modest, et al.

#616O
胃癌および胃食道接合部癌

Pertuzumab (P) + Trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a phase III study (JACOB)

Josep Tabernero, et al.

#617O
胃癌および食道胃接合部癌

A phase III study of Nivolumab in previously treated advanced gastric or gastroesophageal junction cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)

Narikazu Boku, et al.

Poster Discussion session

#620PD
膵癌

YOSEMITE: A 3 arm double-blind randomized phase 2 study of Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (Abraxane®) and Placebo (GAP) versus Gemcitabine, Abraxane® and either 1 or 2 truncated courses of Demcizumab

Antonio Cubillo, et al.

#626PD
胃癌

A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)

Takaki Yoshikawa, et al.

Poster Display session

#555P
大腸癌

Analysis of angiogenesis biomarkers for Ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase 3 study

Josep Tabernero, et al.

#671P
胃癌および食道胃接合部癌

Interim safety and clinical activity of Nivolumab in combination with S-1/Capecitabine plus Oxaliplatin in patients with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction cancer: Part 1 study of ATTRACTION-04 (ONO-4538-37)

Yoon-Koo Kang, et al.